Promisingly for the translation of this insight into the practice of prostate cancer drug development, the AKT inhibitor ML-9 has recently been found effective at inducing prostate cancer cell death in vitro in a calcium-dependent manner [104]. This evidence concerns the gene AKT1 and Familial prostate cancer.